Nov 29, 2023 / 02:10PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Pleasure to have Amgen management with us today. I feel like between Shawn, (inaudible) and myself covering Amgen for like 14 years now, I have not seen this type of setup come up in terms of pipeline readouts for Amgen in a long time. So I'm very curious what's on top of your mind, Peter, I want to jump right into it.
Peter H. Griffith - Amgen Inc. - Executive VP & CFO
Great, Umer. Well, thank you for inviting us. With me today, Paul Burton, our Chief Medical Officer; Justin Claeys, our Vice President of Investor Relations. So we're delighted to be here and strong execution driving innovation at speed and scale.
So three points to make there following up on what shared with the group. We've closed Horizon. We've added a Rare Disease business, demonstrating our willingness to pursue the best innovation, whether it's internal or external. And second, to your point, driving our pipeline, rapidly advancing a number of first-in-class,
Amgen Inc at Evercore ISI HealthCONx Conference Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers